Answers are grounded in this paper and cite their sources.
Objective: To compare the clinical effectiveness, safety, and respiratory therapist-reported usability of lyophilized and dry powder colistin formulations administered by nebulization for carbapenem-resistant Gram-negative bacterial (CRGNB) pneumonia.Methods: This single-center retrospective before-and-after cohort study included adult intensive care unit patients with hospital-acquired or ventilator-associated pneumonia caused by CRGNB who received nebulized colistin for ≥72 hours.Patients treated from January 2025 to February 2026 received dry powder colistin, whereas those treated from March to July 2026 received the lyophilized formulation.Both formulations were administered at 133.6 mg colistin base activity every eight hours using the same jet nebulizer.The primary outcome was favorable clinical response on day 14.Secondary outcomes included clinical response on Days 7 and 28, microbiological eradication on Days 7, 14, and 28, mortality, adverse events, and respiratory therapist-reported usability.Results: A total of 50 patients were included, with 20 in the lyophilized colistin group and 30 in the dry powder colistin group.Both groups had comparable baseline characteristics and disease severity, including APACHE II scores.Day-14 favorable clinical response rates were comparable between groups (65.0% vs. 63.3%;p=0.904).No significant differences were observed in clinical response, microbiological eradication, in-hospital mortality, or pneumonia-related mortality.However, although these differences did not reach statistical significance, numerically higher day-7 clinical response (90.0% vs. 76.7%) and microbiological eradication rates (90.0% vs. 66.7%) were observed with the lyophilized formulation.No bronchospasm or acute kidney injury occurred.Respiratory therapists reported significantly shorter reconstitution and nebulization times, less impact on daily workload, and less frequent nebulizer cup overflow with the lyophilized formulation (all p<0.001).Conclusion: Lyophilized and dry powder nebulized colistin demonstrated comparable overall clinical effectiveness and safety in CRGNB pneumonia.However, the lyophilized formulation provided substantially greater usability and administration efficiency.Larger prospective studies are needed to determine whether its favorable early clinical and microbiological trends translate into meaningful clinical benefits.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: